Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improves progression-free survival

2012 ASCO Annual Meeting

Published: 2 Jun 2012

Views: 4021

Rating:

Save

Dr Eric Pujade-Lauraine - Université Paris Descartes, France

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Eric Pujade-Lauraine presented results from a phase III randomised trial that added bevacizumab to standard chemotherapy which doubled progression-free survival in women with platinum-resistant ovarian cancer.

Related Videos

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Choosing Wisely in endometrial & cervix cancers: Medical therapy

Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India

Choosing Wisely in endometrial & cervix cancers: Medical therapy ( Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

Choosing Wisely in radiology

Dr Iramu Revelian - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology ( Dr Iramu Revelian - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

More from ecancer